NeuroSense Therapeutics Ltd. (NRSNW)Herzliya, Israel | NasdaqCM
0.01 USD
|
Hot Take ↕ | Oct. 10, 2026, 9:18 a.m. EDT
The immediate outlook is severely bearish due to a catastrophic liquidity crisis. The company possesses negative book value, massive negative free cash flow, and a current ratio of just 0.31, indicating it cannot cover its short-term liabilities. With no analyst recommendations and a complete absence of price history or dividend track record, there is no foundation for a recovery thesis. The recent news of the CFO acquiring shares in a private placement is a classic 'distress sale' signal, suggesting insiders are buying the dip because they believe the public market is mispricing the imminent failure, rather than signaling a turnaround. Without any revenue growth, positive earnings, or a fortress balance sheet to support a long-term hold, this security represents a high-risk speculative bet on a potential miracle rather than a sound investment. |
| Attribute | Value |
|---|---|
| Beta | 1.64 |
| Website | https://www.neurosense-tx.com |
| Attribute | Value |
|---|---|
| Address1 | Building B |
| Address2 | 11 HaMenofim Street |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 1.637 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | -0.958 |
| City | Herzliya |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0105 |
| Current Ratio | 0.309 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0105 |
| Day Low | 0.0105 |
| Ebitda | -11,069,000 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -0.935 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0105 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.0105 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.0105 - 0.0105 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 1,193,534 |
| Free Cashflow | -3,869,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 0.0105 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,021-12-09 |
| Language | en-US |
| Long Business Summary | NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. |
| Long Name | NeuroSense Therapeutics Ltd. |
| Market | us_market |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_551904618 |
| Net Income To Common | -11,125,000 |
| Open | 0.3 |
| Operating Cashflow | -7,671,000 |
| Operating Margins | 0.0 |
| Phone | 972 9 799 6183 |
| Previous Close | 0.0105 |
| Price Hint | 4 |
| Price To Book | -0.010960334 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.079 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.0105 |
| Regular Market Day Low | 0.0105 |
| Regular Market Day Range | 0.0105 - 0.0105 |
| Regular Market Open | 0.3 |
| Regular Market Previous Close | 0.0105 |
| Regular Market Price | 0.0105 |
| Regular Market Time | 1,792,075,373 |
| Regular Market Volume | 6 |
| Return On Assets | -2.47301 |
| Return On Equity | -21.749762 |
| Sand P52 Week Change | 0.16207206 |
| Sector | |
| Sector Key | |
| Short Name | NEUROSENSE THERAPEUTICS LTD C/W |
| Source Interval | 15 |
| Symbol | NRSNW |
| Total Cash | 166,000 |
| Total Cash Per Share | 0.094 |
| Total Debt | 170,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.935 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 6 |
| Website | https://www.neurosense-tx.com |
| Zip | 4,672,562 |